Trial Profile
A Phase 2, Open-Label, Pharmacodynamic Study to Evaluate the Effect of Sotatercept (ACE-011) on Red Blood Cell Mass and Plasma Volume in Subjects With Solid Tumors
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 30 Nov 2023
Price :
$35
*
At a glance
- Drugs Sotatercept (Primary)
- Indications Chemotherapy-induced anaemia
- Focus Therapeutic Use
- Sponsors Celgene Corporation; Merck Sharp & Dohme
- 24 Dec 2014 New trial record